Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Serum Isolevuglandin IgG Antibody Concentrations Are Increased in Patients with Systemic Lupus Erythematosus and Associated with Lower 24-Hour Blood Pressure.

Frontiers in lupus·2026
Same author

ImmuSeeker: deep mining of immune-related gene family signatures through lineage reconstruction.

Genome biology·2026
Same author

A Mendelian randomization-based drug repurposing pipeline: application to lipid traits and coronary artery disease.

medRxiv : the preprint server for health sciences·2026
Same author

Association of Clonal Hematopoiesis With Incident, Late-Onset, Seropositive Rheumatoid Arthritis.

Arthritis & rheumatology (Hoboken, N.J.)·2026
Same author

Association between genetically predicted expression of TPMT and azathioprine adverse events.

BMC pharmacology & toxicology·2026
Same author

Association of Pregabalin vs. Duloxetine with Cardiovascular Events: A Retrospective Cohort Study Among US Veterans With Chronic Musculoskeletal Pain.

Clinical pharmacology and therapeutics·2026

Related Experiment Video

Updated: May 11, 2026

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Warfarin pharmacogenomics in children.

Susan I Vear1, C Michael Stein, Richard H Ho

  • 1Pediatric Heme/Onc, Vanderbilt University/Monroe Carell Jr Children's Hospital, Nashville, Tennessee, USA.

Pediatric Blood & Cancer
|May 18, 2013
PubMed
Summary
This summary is machine-generated.

Pharmacogenomics, or how genes affect drug response, is key for warfarin dosing in children. This review explores CYP2C9 and VKORC1 gene variants and their impact on pediatric warfarin therapy.

Keywords:
CYP2C9VKORC1pharmacogenomicswarfarin

Related Experiment Videos

Last Updated: May 11, 2026

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Area of Science:

  • Pharmacology
  • Genetics
  • Pediatric Medicine

Background:

  • Warfarin is a widely used oral anticoagulant with a narrow therapeutic index.
  • Frequent International Normalized Ratio (INR) monitoring is essential for effective warfarin therapy.
  • The influence of pharmacogenomics on warfarin response is established in adults but less understood in children.

Purpose of the Study:

  • To review the role of CYP2C9 and VKORC1 genetic variants in warfarin response.
  • To summarize current knowledge of warfarin disposition and pharmacogenomics in pediatric patients.
  • To discuss the implications of pharmacogenetic-based warfarin dosing in children.

Main Methods:

  • Literature review of pharmacogenomic studies related to warfarin.
  • Focus on CYP2C9 and VKORC1 gene variants.
  • Analysis of recent pediatric warfarin pharmacogenetic research.

Main Results:

  • CYP2C9 and VKORC1 variants significantly impact warfarin pharmacokinetics and pharmacodynamics.
  • Limited but growing evidence suggests pharmacogenomic factors influence warfarin response in children.
  • Pediatric studies on warfarin pharmacogenomics are emerging.

Conclusions:

  • Pharmacogenomic insights into CYP2C9 and VKORC1 are crucial for optimizing pediatric warfarin therapy.
  • Further research is needed to develop and validate pharmacogenetic-based dosing algorithms for children.
  • Personalized warfarin dosing in pediatric patients holds significant clinical potential.